Reactogenicity and Immunogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated Vaccines

COVID-19 Clinical Trial

Official title:

Reactogenicity and Immunogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated Vaccines

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05095298
• Other study ID #: BOOST
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: August 1, 2021
• Est. completion date: August 1, 2022

Study information

• Verified date: February 2022
• Source: Huashan Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group. Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention. Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 400
• Est. completion date: August 1, 2022
• Est. primary completion date: March 15, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years old,

• Through asking medical history and physical examination, the investigator judged that the health condition is good: the chronic disease is stable and there is no change within 3 months of medication;

• has been completed 2 doses of Covid-19 Inactivated vaccine 4-8 months ago;

• Female participants of childbearing age who were not breast-feeding or pregnant (negative blood pregnancy test), and had no family planning in the first 3 months after enrollment and took effective contraceptive measures. Take effective contraceptive measures within 2 weeks before inclusion;

• Volunteered to receive the third dose of vaccine.And during the entire follow-up research period, be able and willing to complete the entire prescribed research plan; Have the ability to self-understand research procedures, informed consent & voluntarily sign informed consent, and be able to comply with the requirements of the plan

Exclusion Criteria:

• RT-qPCR detects active SARS-Cov-2 infection;

• a history of COVID-19, SARS, MERS infection (self-report, on-site inquiry);

• a high-risk factor for COVID-19 infection:

• a history of close contact with people infected with the new coronavirus, a history of living in high-risk areas, and a history of contact with patients with fever or respiratory symptoms in high-risk areas or abroad.

• Fever, dry cough, fatigue, nasal congestion, runny nose, sore throat, myalgia, diarrhea, shortness of breath, dyspnea, etc. 7 days before enrollment;

• receiving COVID-19 booster vaccination;

• allergic to the active ingredients of the SARS-CoV-2 vaccine, any of the inactive ingredients, the substances used in the production process, or those who have had allergies during previous vaccination of similar vaccines;

• those who have had severe allergic reactions to vaccines in the past (such as acute allergic reactions, angioedema, respiratory Difficulties, urticaria, angioedema or abdominal pain);

• body temperature >37.0? before vaccination;

• blood pregnancy test positive;

• with uncontrolled epilepsy and other serious neurological diseases (such as transmissive myelitis, Guillain-Barre syndrome) , Demyelinating diseases, etc.), or have a history or family history of encephalopathy or mental disease;

• severe liver and kidney disease, uncontrollable hypertension (systolic blood pressure =180 mmHg, diastolic blood pressure =100 mmHg), diabetic complications, Malignant tumors, various acute diseases or acute attacks of chronic diseases;

• diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases;

• receiving anti-tuberculosis treatment;

• a history of coagulopathy ( Such as coagulation factor deficiency, coagulation disease) within 3 months of subjects receiving immunotherapy or inhibitor therapy (continuous oral or infusion for more than 14 days), or after 3 months of hormone therapy, the average daily dose is =20mg/day (Prednisone);

• Receiving live attenuated vaccine within 1 month before this vaccination, other vaccines within 14 days before this vaccination;

• Receiving other research drugs within 3 months before vaccination; participating in other research vaccines Or subjects in clinical trials of research drugs;

• other conditions that the investigator judges are not suitable for this clinical trial;

Related Conditions & MeSH terms

• COVID-19

Intervention

Drug:
• Vaccine, COVID19
It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group. Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention. Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.

Locations

Country	Name	City	State
China	Beijing Ditan Hospital Capital Medical University	Beijing
China	Huashan Hospital affiliated to Fudan University	Shanghai	Jingan

Sponsors (1)

Lead Sponsor	Collaborator
Huashan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immunogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated Vaccines	Observe the 28th day of the subjects' pseudovirus neutralizing antibody geometric mean titers (GMTs) and mean geometric titers fold growth (GMFR) changes	Day 28
Primary	Reactogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated Vaccines	All solicited and non-solicited adverse events within 28 days.	Day 28
Secondary	The seropositive rate of neutralizing antibodies	The seropositive rate of neutralizing antibodies after third vaccination shots	3 days/14 days/28days/45days/60 days/90 days/180 days/365 days
Secondary	GMT of neutralizing antibodies	GMT of neutralizing antibodies after third vaccination shots	3 days/14 days/28days/45days/60 days/90 days/180 days/365 days
Secondary	GMFR of neutralizing antibodies	GMFR of neutralizing antibodies after third vaccination shots	3 days/14 days/28days/45days/60 days/90 days/180 days/365 days
Secondary	severe adverse events and adverse events of special interest	severe adverse events and adverse events of special interest	up to 1 year